Scientific Agenda

Thursday, October 24, 2013

8:00 am

Welcome

MYELOMA SESSION

8:15 am

Introduction to Myeloma Session

Session I: Translational science and its impact on clinical care

8:20 am

Gene profiling/exon sequencing: Clonal evolution in myeloma

8:40 am

Integrative whole transcriptome sequencing and cyclins in myeloma and MCL therapy

9:00 am

The other stem cell in Myeloma: CD34+ mobilization, exhaustion, and SPMs

9:20 am

Panel discussion and questions

9:30 am

Coffee break

Session II: Special considerations in Myeloma

9:50 am

Pre-session audience survey

9:55 am

MRD evaluation in myeloma: The future is here

10:15 am

High risk myeloma, what do we know, where are we going?

10:35 am

Smoldering myeloma: who and when to treat; should smoldering high risk myeloma be immediately treated?

10:55 am

New paradigms, new treatments in relapsed/refractory disease: An update

11:15 am

Post-session audience survey, panel discussion and questions

11:30 am

Lunch

Session III: Special Topics in Myeloma

1:20 pm

Presentation of best myeloma abstract

1:30 pm

The SASS Foundation for Medical Research Award Ceremony
Presentation: Joseph Michaeli Award for Contributions to Myeloma Research

1:35 pm

Amyloidosis: Past, present, and future

1:55 pm

Panel Discussion

Session IV: Myeloma treatment

2:00 pm

Pre-debate audience survey
Debate: Should alkylators be used upfront in transplant-ineligible patients?

Post-debate audience survey

2:30 pm

Pre-debate audience survey
Debate: What is the best induction therapy in transplant-eligible patients?

Post-debate audience survey

3:00 pm

Pre-debate audience survey
Debate: To maintain or not to maintain?

Post-debate audience survey

3:30 pm

Panel discussion and questions

3:40 pm

Coffee Beak

Session V: Innovative therapies in Myeloma

4:00 pm

Optimal use of transplantation: Early, late, non-ablative?

4:20 pm

Immunologic approaches: elotuzumab, vaccines – MAGE and others, allogeneic transplant

4:40 pm

Panel discussion and questions

4:50 pm

Adjourn

Friday, October 25, 2013

8:00 am

Welcome

CLL SESSION

8:05 am

Introduction to CLL Session

Session VI: Basic science and its application to the clinic

8:10 am

Pre-session audience survey

8:15 am

Etiology of CLL: A Primer on B-cell signaling

8:35 am

Primer on kinase inhibition

8:55 am

Immunodeficiency in CLL: Its manifestations and management

9:15 am

Autoimmunity in CLL

9:35 am

Post-audience survey, panel discussion and questions

9:50 am

Coffee break

10:10 am

Long-term toxicity of therapy

10:30 am

Pre-debate survey question
Debate: Do we have enough data to eliminate chemotherapy from initial treatment for CLL? Can kinase inhibitors and IMiDs replace chemotherapy?

Post-debate survey question

11:00 am

Panel discussion

11:10 am

Lunch

Session VIII: Approaches to therapy II

1:00 pm

How to manage p53 mutated CLL

1:20 pm

The use of prognostic markers in clinical practice

1:40 pm

Pre-debate audience survey
Debate: Which is the optimal approach? BR or FCR/FR

Post-debate audience survey

2:10 pm

CART Therapy

2:30 pm

Post-session audience survey, panel discussion and questions

2:40 pm

Coffee break

Session IX: Special Topics in CLL and Waldenstrom’s macroglobulinemia

3:00 pm

Introduction to the Prince Family Lecture

Hairy cell leukemia: New targets, new therapy

3:30 pm

Introduction to the Bruce Waterfall Memorial Lecture

Waldenstrom’s macroglobulinemia therapy in the era of novel therapies

4:00 pm

Panel discussion and questions

4:15 pm

Adjourn

Saturday, October 26, 2013

8:00 am

Welcome and audience survey

LYMPHOMA SESSION

8:05 am

Introduction to Lymphoma Session

Session X: Genetic, epigenetics, and other molecular changes in lymphoma

8:10 am

New and epigenetic targets in lymphoma

8:30 am

HGAL and LMO2 in B cell malignancies –

8:50 am

Tumor heterogeneity and tumor sequencing in DLBCL

9:10 am

Immunomodulation of NK cells for the treatment of lymphoid malignancies

9:30 am

Panel discussion and questions

9:40 am

Coffee break

Session XI: Hodgkin Disease

10:00 am

Pre-session audience survey

10:05 am

How can we make Hodgkin’s disease therapy less toxic and more effective?

10:25 am

Debate: Recurrent HL after auto transplant in CR on brentuximab vedotin: Allo transplant or maintenance therapy?

10:55 am

What does the future hold for advanced stage Hodgkin Lymphoma?

11:15 am

Post-session audience survey, panel discussion and questions

Session XII: Special Lectures in Lymphoma

11:30 am

Presentation of best lymphoma abstract

11:40 am

The SASS Foundation for Medical Research Award Ceremony

Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for Contributions to Lymphoma Research

11:45 am

Highlights from Lugano: The 12th International Conference on Malignant Lymphoma

12:05 pm

Panel discussion

12:10 pm

Lunch

Session XIII-A: Controversies in Lymphoma I

Parallel with Session XIII-B: Controversies in Lymphoma II

2:10 pm

Is there still a role for radiation in limited stage follicular lymphoma?

2:30 pm

Is there long term benefit from maintenance rituximab?

2:50 pm

Recurrent follicular lymphoma: Novel approaches vs stem cell transplant

3:10 pm

Do we really need to transplant young patients with mantle cell lymphoma?

3:30 pm

Panel discussion and questions

3:45 pm

Adjourn

Session XIII-B: Controversies in Lymphoma II

Parallel with Session XIII-A: Controversies in Lymphoma I

2:10 pm

How can we improve our therapy for T-cell lymphoma? Should certain therapeutic options be brought upfront?

2:30 pm

Debate: Is EPOCH-R really better than R-CHOP +/- XRT in myc+ ABC DLBCL?

3:00 pm

Debate: Optimal frontline therapy for follicular lymphoma: Do we need to start with chemotherapy?

3:30 pm

Kinase inhibitors in B cell lymphomas: What does the future hold?

3:50 pm

Panel discussion and questions

4:00 pm

Adjourn